Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Read Article
News
2024
2023
Archive
Search news articles
December 16, 2021
Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders
December 14, 2021
Cidara Therapeutics and Mundipharma Announce Positive Topline Results From the Global Phase 3 Pivotal ReSTORE Tiral of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
December 10, 2021
CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone
December 8, 2021
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma
December 6, 2021
Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company
December 3, 2021
CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
December 3, 2021
Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
November 22, 2021
Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutics Candidate to Treat Alcohol Use Disorder
November 19, 2021
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
November 17, 2021
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
1
2
3
…
16
Next Page »